Janus kinase inhibitors (JAKi) – Updated recommendations to minimise risks associated with medicine
13/03/2023
Medicines for human use
Direct healthcare professional communication (DHPC)
Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib), Rinvoq (upadacitinib) and Xeljanz (tofacitinib) – Updated recommendations to minimise the risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality with use of Janus kinase inhibitors (JAKi).